ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "innate immunity"

  • Abstract Number: 0040 • ACR Convergence 2023

    Non-canonical NF-κB Signalling Is Required for Extrathymic AIRE Expression and Immunoregulatory Molecules in Cells of the Dendritic Lineage

    Guus van Laar1, Leonie Huitema1, Boy helder1, Joanna Fergusson1, Hergen Spits1, Jan Piet van Hamburg1 and Sander Tas2, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Amsterdam UMC, locatie AMC, Utrecht, Netherlands

    Background/Purpose: The transcription factor Autoimmune Regulator (AIRE) is crucial for the establishment of central tolerance in the thymus. Recently, peripheral CD45+ extrathymic AIRE-expressing cells (eTACs)…
  • Abstract Number: 0940 • ACR Convergence 2023

    A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome

    Françis Bonnefoy1, Susanne Behlke2 and Sylvain Perruche1, 1Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Institute/MedINNPharma, Besançon, France, 2MedINNPharma, Besançon, France

    Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…
  • Abstract Number: 0041 • ACR Convergence 2023

    Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment

    Jia Li, Yanrong Cai, Xin Guan, Meike Ewald, Lars-Oliver Tykocinski, Hanns-Martin Lorenz and Theresa Tretter, Department of Internal Medicine V, Div. of Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Activated macrophages (Mph) can be subdivided in at least 2 major subgroups according to their polarization into classical pro-(M1-Mph) or anti-inflammatory (M2-Mph) subtypes. Together…
  • Abstract Number: 0947 • ACR Convergence 2023

    Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis

    Amela Hukara1, Gino Andrea Bonazza1, Tracy Tabib2, Raphael Micheroli1, Suzana Jordan3, Kristina Bürki1, Sylvie Schlitz Schönbächler1, Adrian Ciurea4, Oliver Distler3, Robert Lafyatis5, Przemyslaw Blyszczuk1 and Gabriela Kania1, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 4University Hospital Zurich, Zürich, Switzerland, 5University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Fcy receptors (FcγR) are opsonic phagocytic receptors, requiring tight regulations to prevent uncontrolled activation of pro-inflammatory phagocytosis. SSc macrophages display an alternatively-activated profibrotic phenotype.…
  • Abstract Number: 0049 • ACR Convergence 2023

    Soluble Uric Acid Is an Endogenous Inhibitor of CD38

    Shijie Wen1, Hiroshi Arakawa1, Shigeru Yokoyama2, Yoshiyuki Shirasaka1, Haruhiro Higashida3 and Ikumi Tamai1, 1Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan, 2Research Center for Child Mental Development, Kanazawa University; Division of Socio-Cognitive-Neuroscience, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Kanazawa University, Kanazawa, Japan, 3Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan

    Background/Purpose: CD38 is the main NAD+-degrading enzyme that plays a key role in innate immunity, aging, cancer, and metabolic disorders. Pharmacological inhibition of CD38 has…
  • Abstract Number: 1329 • ACR Convergence 2023

    R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis

    Yan Chen1, Sothy Yi1, Vadim Markovtsov1, Bhushan Samant1, Andrew Chow1, Esteban Masuda1 and Simon Shaw2, 1Rigel Pharmaceuticals, Inc, South San Francisco, CA, 2Rigel Pharmaceuticals, Inc., South San Francisco, CA

    Background/Purpose: The Toll-Like Receptor family (except TLR3) signal through IRAK4 and IRAK1 to produce an array of cytokines (including IL-6, IL-23 and TNFα in response…
  • Abstract Number: 0050 • ACR Convergence 2023

    Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease

    Maarten van der Linden1, Sangeeta Kumari1, Daphne Montizaan1, Stephanie van Dalen1, Annemarie Kip1, Martyn FOSTER2, Inge Reinieren1, Elsa Neubert3, Luise Erpenbeck4, Tirza Bruurmijn1, Peter van Zandvoort1, Paul Vink1, Eric Meldrum5, Helmuth van Es1 and Renato Chirivi1, 1Citryll BV, Oss, Netherlands, 2Experimental Pathology Consultancy, Benfleet, United Kingdom, 3Leiden Academic Centre for Drug Research, Leiden, Netherlands, 4University Medical Center Münster, General Dermatology and Venereology, Münster, Germany, 5Citryll BV, Basel, Switzerland

    Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of multiple inflammatory and autoimmune diseases (Chirivi et al., 2021; DOI: 10.1038/s41423-020-0381-3). Targeting the NETosis pathway…
  • Abstract Number: 1498 • ACR Convergence 2023

    First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

    Giorgio Senaldi1, Aparna Mohan1, Li Zhang1, Jun Tanaka2, Grishma Pandya3, Sindee Grossman3, Sarah Urbina4, Steven Reynolds5 and Alan Hand4, 1Daiichi Sankyo, Basking Ridge, NJ, 2Daiichi Sankyo, Inc., Basking Ridge, NJ, 3Daiichi Sankyo Inc., Basking Ridge, NJ, 4Worldwide Clinical Trials, San Antonio, TX, 5Cenexel, Los Alamitos, CA

    Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor, whose ligands include nucleic acids and whose activation is part of the pathogenesis of systemic lupus…
  • Abstract Number: 0051 • ACR Convergence 2023

    CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis

    Nicole McDermott1, Thomas Macleod1, Ala Altaie1, Liz Straszynski2, Robert Dunsmuir3, Vishal Borse3, Peter Loughenbury3, Davide Simone4, Stevephen Sansom4, Christopher Buckley4 and Dennis McGonagle5, 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2Leeds Institute of Medical Research at St. James’s, Leeds, United Kingdom, 3Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom, 4Kennedy Institute of Rheumatology, Oxford, United Kingdom, 5Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: IL-23 is a key cytokine involved in diseases such as psoriasis, psoriatic arthritis and spondyloarthropathies (SpA) and inflammatory bowel disease.IL-23 is produced by activated…
  • Abstract Number: 1587 • ACR Convergence 2023

    Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity

    Benjamin Klein, Mack Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Amanda Victory, Shannon Loftus, Mary O'Riordan and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Autoimmune photosensitivity is observed in type I Interferon (IFN) mediated diseases such as systemic and cutaneous lupus erythematosus (SLE/CLE) and dermatomyositis. Type I IFN…
  • Abstract Number: 0056 • ACR Convergence 2023

    The Activation of cGAS-STING Pathway in Systemic Lupus Erythematosus

    Jie An1, Stephen Wilson2, Jill Henault3 and Keith Elkon1, 1University of Washington, Seattle, WA, 2Bristol Myers Squibb, Cambridge, MA, 3Bristol Myers Squibb, Acton, MA

    Background/Purpose: The majority of patients with SLE show a striking Type I Interferon (IFN-I) signature in their peripheral blood. Although this signature can be generated…
  • Abstract Number: 1662 • ACR Convergence 2023

    Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency

    Jemy Varghese1, Scott Canna1, Emily Landy2, Laurence Eisenlohr1, Elise Peauroi3, Vinh Dang1, Anastasia Frank-Kamenetskii4 and Jeremy Morrissette5, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA, 4CHOP/UPENN, Philadelphia, PA, 5University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS) are associated with highly elevated peripheral blood levels of the inflammasome-activated cytokine IL-18 and…
  • Abstract Number: 0259 • ACR Convergence 2023

    Preliminary Experience with a Novel “Fix” for Deep Epitope and Transcriptional Phenotyping of Fragile Cells from Autoinflammatory Flares

    Hallie Carol1, Emily Landy2 and Scott Canna1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Autoinflammatory diseases (AID) are characterized by inflammation and immunopathology due to primary defects in the innate immune response. Neutrophils (PMN) feature prominently in the…
  • Abstract Number: 1676 • ACR Convergence 2023

    Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology

    Paula David1, Thomas Macleod2, Yu Shi3, Payal Ganguly1, Cedric Duval3, Mark Harland1, Chi Wong1, Benazir Saleem4 and Dennis McGonagle5, 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, 2University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 3Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, 5Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…
  • Abstract Number: 0757 • ACR Convergence 2023

    Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals

    Pierre-Antoine Juge1, Gregory McDermott2, Keigo Hayashi2, Jing Cui3, Clémence David-Gabarre4, Marie-Louis Frémond4, Holly Wobma5, Soumya Raychaudhuri2, Elizabeth Karlson2, Philippe Dieudé6 and Jeffrey Sparks7, 1Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Imagine, Paris, France, 5Division of Immunology, Boston Children's Hospital, Boston, MA, 6Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, 7Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: COPA syndrome is a rare, severe monogenic autoinflammatory/autoimmune disorder with variable penetrance, most commonly affecting the lungs and joints. It is caused by dominant…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology